• Keine Ergebnisse gefunden

Table 2s.

N/A
N/A
Protected

Academic year: 2022

Aktie "Table 2s."

Copied!
1
0
0

Wird geladen.... (Jetzt Volltext ansehen)

Volltext

(1)

Table 2s. Change of radiotherapy planning in 22 patients

Patient No. Age Planning RT RT dosage

1 77 Prostatic bed 74 Gy / 37 fr

2 70 Lymph node SBRT 35 Gy / 5 fr

3 75 Prostatic bed and Lymph node 70 Gy / 35 fr / SBRT 30 Gy / 5 fr

4 59 Prostatic bed HYPO 66 Gy / 30 fr

5 69 Lymph node SBRT 35 Gy / 5 fr

6 75 Prostatic bed 74 Gy / 37 fr

7 64 Prostatic bed and Lymph node HYPO +SIB 66 Gy / 30 fr + 54 Gy / 30 fr

8 70 Prostatic bed HYPO +SIB 66 Gy / 30 fr + boost 70.5 Gy

9 77 Prostatic bed 70 Gy / 35 fr

10 71 Prostatic bed 70 Gy / 35 fr

11 81 Prostatic bed HYPO 66 Gy / 30 fr

12 76 Prostatic bed HYPO 66 Gy / 30 fr

13 61 Prostatic bed and Lymph node HYPO +SIB 61.6 Gy / 28 fr + 50.4 Gy / 28 fr

14 63 Prostatic bed 70 Gy / 35 fr

15 71 Prostatic bed HYPO +SIB 66 Gy / 30 fr + boost 70.5 Gy

16 76 Prostatic bed 70 Gy / 35 fr

17 63 Prostatic bed 70 Gy / 35 fr

18 76 Prostatic bed 70 Gy / 35 fr

19 54 Prostatic bed 70 Gy / 35 fr

20 70 Lymph node SBRT 27 Gy / 3 fr

21 59 Prostatic bed 70 Gy / 35 fr

22 74 Prostatic bed HYPO 66 Gy / 30 fr

Gy=gray; fr=fractions; SBRT=Stereotactic Body Radiation Therapy; HYPO= hypofractioned radiotherapy; SIB=simultaneous integrated boost;

(2)

Referenzen

ÄHNLICHE DOKUMENTE

Christian Mölleken,

[r]

Total patients in RISE represents patients in RISE, aged 18 years and older, at least 2 visits with >= 30 days apart during the study period with

TESCC, thoracic esophageal squamous cell carcinoma; ASA-PS, ; Ut, Upper thoracic esophagus; Mt, Middle thoracic esophagus; Lt, Lower thoracic esophagus; NAC,

Yet, without post-surgery radiotherapy, survival does not increase with gross total resection compared to biopsy only, underlining the role of radiotherapy (Fig. 2A, B), and the

* For patients without individual dose estimates for previous PRRT, a replacement dose assuming 0.7 Gy/GBq 177 Lu-DOTATOC, 2.1 Gy/GBq 90 Y- DOTATOC or 1.6 Gy /GBq 213 Bi-DOTATOC

• The proportions of households in high- and non-high-publicity areas were the same (77 percent) for households that recognized the ENERGY STAR label (aided), knowingly purchased

The cumulative incidence of OM (grade 1–4) was 97.3% in the selenium and 100% in placebo group (p value: 0.79), and difference in the mean serum selenium level at the end of